• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Atomic 25, 40, 60
    / Unipharm


    Active Ingredient
    Atomoxetine (as HCl) 25, 40, 60 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    28 X 25 mg

    not in the basket chart 11107

    Film Coated Tablets

    28 X 40 mg

    not in the basket chart 11114

    Film Coated Tablets

    28 X 60 mg

    not in the basket chart 11115

    Related information


    Dosage

    Dosing of paediatric population up to 70 kg Body WeightThe drug should be initiated at a total daily dose of approximately 0.5 mg/kg. The initial dose should be maintained for a minimum of 7 days prior to upward dose titration according to clinical response and tolerability. The recommended maintenance dose is approximately 1.2 mg/kg/day (depending on the patient’s weight and available dosage strengths of atomoxetine.
    Dosing of paediatric population over 70 kg Body Weight and AdultsThe Drug should be initiated at a total daily dose of 40 mg. The initial dose should be maintained for a minimum of 7 days prior to upward dose titration according to clinical response and tolerability. The recommended maintenance dose is 80 mg. The maximum recommended total daily dose is 100 mg.


    Indications

    Atomic is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme.
    Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist.
    Diagnosis should be made according to current DSM criteria or the guidelines in ICD.
    In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed.
    Third-party corroboration is desirable and Atomic should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.


    Contra-Indications

    Hypersensitivity to active substance or to any of its excipients.
    Combination with monoamine oxidase inhibitors (MAOI). Atomoxetine should not be used within a minimum of 14 days  after discontinuing therapy with MAOI. Treatment with MAOI should not be initiated within 14 days after discontinuing atomoxetine.
    Patients with narrow-angle glaucoma.
    Patients with pheochromocytoma.
    Patients with severe cardiac/vascular disorder, hypertension, tachycardia.


    Manufacturer
    Trima Israel Pharmaceutical Products Maabarot Ltd. Israel
    CLOSE